A clinical trial of a vaccine for Brachyury-positive tumors is currently underway in patients with solid tumours, as a result of further evidence supporting the hypothesis that Brachyury may be an important potential target for tumor therapy (22). This evidence concerns the gene TBX1 and neoplasm.